Related Experiment Video

Updated: Jun 5, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Combined modality therapy with TRAIL or agonistic death receptor antibodies

Hope M Amm1, Patsy G Oliver, Choo Hyung Lee

  • 1Department of Pharmacology and Toxicology, University of Alabama at Birmingham, USA.

Cancer Biology & Therapy
|January 26, 2011
PubMed

Insights

Chemotherapy can enhance tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) therapies by sensitizing resistant cancer cells. Understanding these mechanisms is key for developing effective combination cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Molecularly targeted therapies, including antibodies and small molecule inhibitors, represent a significant advancement in cancer treatment.
  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) therapy is under development for its cancer-specific apoptosis-inducing properties.
  • Cancer cell sensitivity to TRAIL-based therapies varies, with some cell lines exhibiting resistance.

Purpose of the Study:

  • To review the mechanisms by which chemotherapy enhances TRAIL receptor-targeted therapies.
  • To elucidate how chemotherapy sensitizes TRAIL-resistant cancer cells.
  • To identify key pathways for developing effective combination cancer therapies.

Main Methods:

  • Review of preclinical and clinical studies on TRAIL receptor-targeted therapies.
  • Analysis of mechanisms involving modulation of apoptotic pathways (death receptor expression, FLIP, Bcl-2, IAPs).
  • Investigation of cell signaling pathway modulation (NFκB, Akt, p53).

Main Results:

  • Chemotherapy can overcome TRAIL resistance in cancer cells.
  • Mechanisms include upregulation of death receptors and modulation of apoptosis regulators like FLIP and Bcl-2.
  • Chemotherapy impacts cell signaling pathways such as NFκB, Akt, and p53, influencing TRAIL sensitivity.

Conclusions:

  • Chemotherapy enhances TRAIL receptor-targeted therapies by modulating key apoptotic and cell signaling pathways.
  • Understanding these mechanisms is crucial for designing rational combination strategies in cancer treatment.
  • This knowledge can guide the development of novel therapeutic targets for overcoming cancer resistance.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.